2021
TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence
Yu Y, Fan D, Song X, Zakeri K, Chen L, Kang J, McBride S, Tsai CJ, Dunn L, Sherman E, Katabi N, Dogan S, Cracchiolo J, Cohen M, Boyle JO, Lee M, Valero C, Wang J, Wong R, Morris L, Riaz N, Lee N. TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology 2021, 5: 1259-1269. PMID: 34381934, PMCID: PMC8345918, DOI: 10.1200/po.20.00515.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLocoregional failurePatterns of failureCumulative incidenceCell carcinomaPromoter mutationsHPV-positive oropharyngeal squamous cell carcinomaMemorial Sloan-Kettering Cancer CenterRisk of LRFOropharyngeal squamous cell carcinomaNeck squamous cell carcinomaHPV-negative HNSCCsReverse transcriptase (TERT) promoter mutationsOral cavity cancerNext-generation sequencingTERT promoter mutationsDisease subsiteLocoregional recurrenceOverall cohortOverall survivalProspective cohortCancer CenterHuman papillomavirusLaryngopharyngeal cancerUnique pathogenesis
2020
Hot Spot TERT Promoter Mutations Are Rare in Sporadic Pancreatic Neuroendocrine Neoplasms and Associated with Telomere Length and Epigenetic Expression Patterns
Posch A, Hofer-Zeni S, Klieser E, Primavesi F, Naderlinger E, Brandstetter A, Filipits M, Urbas R, Swiercynski S, Jäger T, Winkelmann P, Kiesslich T, Lu L, Neureiter D, Stättner S, Holzmann K. Hot Spot TERT Promoter Mutations Are Rare in Sporadic Pancreatic Neuroendocrine Neoplasms and Associated with Telomere Length and Epigenetic Expression Patterns. Cancers 2020, 12: 1625. PMID: 32575418, PMCID: PMC7352723, DOI: 10.3390/cancers12061625.Peer-Reviewed Original ResearchTelomerase reverse transcriptase (TERT) promoter mutationsPancreatic neuroendocrine neoplasmsSporadic pancreatic neuroendocrine neoplasmsT allele frequencyC250TNeuroendocrine neoplasmsPNEN casesReverse transcriptase (TERT) promoter mutationsDisease-free survivalTrue clinical valueLarge patient cohortPromoter mutationsTERT promoter mutationsParaffin-embedded tissuesPNEN patientsTPM statusClinicopathological informationPatient cohortClinical valueHigh incidenceCancer subtypesAllele frequenciesRelative TLTelomere maintenance mechanismCancer cells
2019
TERT promoter mutations in thyroid cancer: growing evidence for a predictor of poor outcome
Man J, Nicolson N, Gibson C, Carling T. TERT promoter mutations in thyroid cancer: growing evidence for a predictor of poor outcome. Gland Surgery 2019, 8: 301-303. PMID: 31328111, PMCID: PMC6606470, DOI: 10.21037/gs.2019.04.11.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply